Shaping future deprescribing priorities: outcomes of a World Café stakeholder workshop
Date
2025
Authors
Olsen, W.M.
St Pierre, K.
Thompson, W.
Weir, K.R.
Freeman, C.R.
Bohill, R.
Farrell, B.
Langford, A.V.
O’Donnell, L.K.
Reeve, E.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Expert Review of Clinical Pharmacology, 2025; 19(1):85-96
Statement of Responsibility
William Manning Olsen, Kitty St Pierre, Wade Thompson, Kristie Rebecca Weir, Christopher Robert Freeman, Ruth Bohill, Barbara Farrell, Aili Veronica Langford, Lisa Kouladjian O, Donnell, Emily Reeve, Shin J Liau, Aisling Mary McEvoy, Shakti Shrestha, Wubshet Tesfaye, Juanita Breen, Christopher Etherton-Beer, Jerry Yik, Justin Turner and Nagham J Ailabouni
Conference Name
Abstract
Introduction: Medicine-related harm associated with polypharmacy is a pertinent global health chal - lenge. Deprescribing (reducing or stopping) medicines that cause more potential harm than benefit could mitigate the risk of medicine-related harm. However, the existing deprescribing research-to- practice gap threatens the long-term sustainability and scalability of deprescribing efforts. Research design and methods: To address this, key stakeholders including healthcare practitioners, academics, policymakers and representatives of peak professional organizations, gathered at a World Café workshop to reflect on progress achieved in the deprescribing research and practice landscape while exploring the top future priorities for deprescribing. Results: Thirty participants agreed on three top priorities: improving the clinical management of deprescribing; engaging consumers and gaining their perspectives; and raising awareness to enhance communication. Emerging themes and related barriers and catalysts were derived and mapped to a socio-ecological model offering a bird-eye’s view of these factors on an individual, interpersonal, organizational, and societal level. Conclusions: Our World Cafe’ highlights opportunities for future deprescribing research and practice. To promote the uptake of deprescribing in practice, catalysts could include leveraging new technology, promoting deprescribing via social media and optimizing workforce staff and knowledge. Ultimately, this knowledge may motivate deprescribing efforts and bridge the research-to-practice gap
School/Discipline
Dissertation Note
Provenance
Description
OnlinePubl
Access Status
Rights
© 2025 Informa UK Limited, trading as Taylor & Francis Group